|
FY2026
12 months to Jun 30, 2026
|
FY2025
12 months to Jun 30, 2025
|
FY2024
12 months to Jun 30, 2024
|
FY2023
12 months to Jun 30, 2023
|
FY2022
12 months to Jun 30, 2022
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Operating expenses: | |||||
| General and administrative (including stock-based compensation) | |||||
| Depreciation | |||||
| Research and development (including stock-based compensation) | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other (income) expense: | |||||
| Interest income | |||||
| Gain (loss) on disposal of assets | |||||
| Loss on asset impairment | |||||
| Interest expense | |||||
| Gain on debt forgiveness | |||||
| Loss on Impairment | |||||
| Other income | |||||
| Total other expense | |||||
| Net (loss) | |||||
| Net (loss) attributable to the noncontrolling interest | |||||
| Net (loss) applicable to Bion's common stockholders | |||||
| Net (loss) applicable to Bion's common stockholders per basic common share | |||||
| Net (loss) applicable to Bion's common stockholders per diluted common share | |||||
| Weighted-average number of common shares outstanding, Basic | |||||
| Weighted-average number of common shares outstanding Diluted | |||||
Loading...